Deslorelin

Jump to: navigation, search
Deslorelin
Deslorelin.png
Clinical data
Trade namesOvuplant
AHFS/Drugs.comInternational Drug Names
Pregnancy
category
Routes of
administration
implant / Inhalation
ATCvet code
Pharmacokinetic data
Excretionrenal
Identifiers
CAS Number
PubChem CID
UNII
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC64H83N17O12
Molar mass1282.45 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Deslorelin

Articles

Most recent articles on Deslorelin

Most cited articles on Deslorelin

Review articles on Deslorelin

Articles on Deslorelin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Deslorelin

Images of Deslorelin

Photos of Deslorelin

Podcasts & MP3s on Deslorelin

Videos on Deslorelin

Evidence Based Medicine

Cochrane Collaboration on Deslorelin

Bandolier on Deslorelin

TRIP on Deslorelin

Clinical Trials

Ongoing Trials on Deslorelin at Clinical Trials.gov

Trial results on Deslorelin

Clinical Trials on Deslorelin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Deslorelin

NICE Guidance on Deslorelin

NHS PRODIGY Guidance

FDA on Deslorelin

CDC on Deslorelin

Books

Books on Deslorelin

News

Deslorelin in the news

Be alerted to news on Deslorelin

News trends on Deslorelin

Commentary

Blogs on Deslorelin

Definitions

Definitions of Deslorelin

Patient Resources / Community

Patient resources on Deslorelin

Discussion groups on Deslorelin

Patient Handouts on Deslorelin

Directions to Hospitals Treating Deslorelin

Risk calculators and risk factors for Deslorelin

Healthcare Provider Resources

Symptoms of Deslorelin

Causes & Risk Factors for Deslorelin

Diagnostic studies for Deslorelin

Treatment of Deslorelin

Continuing Medical Education (CME)

CME Programs on Deslorelin

International

Deslorelin en Espanol

Deslorelin en Francais

Business

Deslorelin in the Marketplace

Patents on Deslorelin

Experimental / Informatics

List of terms related to Deslorelin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Deslorelin acetate is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist) also known as an LHRH agonist. It stops the production of sex hormones (testosterone and oestrogen).

Deslorelin Acetate is marketed by Peptech with the brand name Ovuplant.[1] It is currently approved for use in veterinary medicine and is used to induce ovulation in mares as part of the artificial insemination process. It is also used to stabilize high-risk pregnancies, mainly of livestock. Unlike other GnRH agonists, which are mainly used to inhibit luteinizing hormone and follicle-stimulating hormone by their ultimate downregulation of the pituitary gland, Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion.

Pharmacokinetics

Deslorelin is a synthetic analogue of a naturally occurring luteinising-hormone releasing hormone (LHRH). Bioavailability is almost complete.

Clinical trials

Deslorelin was successfully trialed in the US and was approved for veterinary use under certain circumstances. In Europe, it was approved for use in equine assisted reproduction.[2]

It is also being trialed in humans to study its efficacy in treatment of breast cancer in women,[3] and in treating precocious puberty and congenital adrenal hyperplasia in male and female children.[4]

As of August 2011 this drug was not approved for general use in the US, other than within approved clinical trials. Orphan drug status has been designated in the US, though approval had not been issued as of 2011.[5]

References

  1. Peptech official Ovuplant site
  2. Deslorelin Acetate - European Agency for the Evaluation of Medicinal Products
  3. Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease - National Cancer Institute
  4. Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia - National Institutes of Health Clinical Center
  5. "Results for Orphan Drug Product Designations Search". FDA. Retrieved 3 September 2011.

Linked-in.jpg